Nanoscope Therapeutics develops optogenetic gene therapies utilizing ambient light-sensitive molecules to restore vision in patients with inherited retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Macular Degeneration. Their proprietary Multi-Characteristic Opsins (MCO) technology delivers light-sensitive proteins to retinal cells, addressing the vision loss caused by the dysfunction of these cells.
Funding
$12.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Inherited retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Macular Degeneration, cause progressive vision loss due to the dysfunction of retinal cells. Current treatments are limited, leaving many patients without effective options to restore their sight.
Solution
Nanoscope Therapeutics is developing gene therapies that utilize Multi-Characteristic Opsins (MCO) to restore vision in individuals affected by inherited retinal degenerative diseases. Their approach involves delivering ambient light-sensitive molecules to retinal cells, enabling these cells to respond to light and compensate for the dysfunction caused by the disease. The company's lead product, MCO-010, is currently in clinical trials for retinitis pigmentosa and is designed to be applicable for patients with complete or partial degeneration of the retina. By correcting the condition at a cellular level, Nanoscope aims to provide a novel therapeutic option for patients with limited treatment alternatives.
Target Audience
The primary target audience includes patients suffering from inherited retinal degenerative diseases, such as Retinitis Pigmentosa, Stargardt Macular Degeneration, and dry AMD, who are experiencing vision loss due to dysfunctional retinal cells.
Features
- Proprietary Multi-Characteristic Opsins (MCO) technology delivers light-sensitive proteins to retinal cells.
- Gene therapy approach targets the underlying cause of vision loss in inherited retinal degenerative diseases.
- MCO-010, the lead product, is in clinical trials for retinitis pigmentosa.
- Applicable for patients with complete or partial degeneration of the retina.
- Aims to restore vision by enabling retinal cells to respond to ambient light.